重庆医科大学汪凯简历 & 招生方向 （2024年11月更新）

    汪凯，男，湖北武汉人，研究员，博士生导师。2012年毕业于中国科学院上海巴斯德研究所，获理学博士学位。硕博连读期间主要从事病毒离子通道研究及抗病毒药物筛选。2015年就职于重庆医科大学，目前主要从事分子病毒学及肝癌代谢研究；围绕代谢与信号转导的交互调控，旨在揭示代谢重编程在肝癌发生发展中的作用，为肝癌治疗提供新的靶点。重医未来医学青年创新团队“病毒感染与代谢重塑研究团队”负责人，先后主持国家自然科学基金3项，重庆市科委及教委课题4项，重庆医科大学“新冠肺炎”应急课题；作为技术骨干承担国家重点研发计划子任务等。以第一作者或通讯作者（含共同）在Clinical Infectious Diseases、Cell Metabolism、Journal of Clinical Investigation、EMBO J、Cell Research、Nature Communications和Signal Transduct Target Ther等期刊发表SCI论文40余篇（含ESI高被引3篇），总引用3400余次，H指数31。入选Elsevier中国金色开放获取高下载论文学者（2020-2021生命科学领域），获2023川渝科学技术学术大会优秀论文特等奖、重庆市期刊优秀论文一等奖、国家发明专利1项。任中国抗癌协会肿瘤代谢专委会青年委员、重庆抗癌协会化疗专业委员会委员，Adv Sci、Nat Commun、Genes & Diseases等期刊审稿人，中国抗癌协会肿瘤代谢专委会青年委员，重庆抗癌协会化疗专业委员会委员。

工作经历：

2024.10- 至今      重庆医科大学  感染性疾病分子生物学重点实验室     研究员

2020.10- 2024.9  重庆医科大学  感染性疾病分子生物学重点实验室     副研究员

2019.10- 2020.9  重庆医科大学  感染性疾病分子生物学重点实验室     副教授

2015.9 - 2019.9   重庆医科大学  基础医学院    病原生物学教研室       讲师

2013.7 - 2015.7   中国科学院    上海生命科学研究院                  博士后

2012.5 - 2013.5   中国科学院   上海巴斯德研究所 分子病毒与免疫重点实验室   助理研究员

研究方向：

    (1)分子病毒学——感染与代谢重塑；

    (2)代谢重编程调控肝癌发生发展的分子机制研究。

    Viruses hijack host cell metabolism for their survival and reproduction. Our group focus on host–pathogen interactions at the metabolic level. We are interested in how viruses alter the metabolism of host cells, and how these changes can be exploited to develop antiviral strategies.

    The metabolic reprogramming induced by oncovirus is critical for the malignant transformation. We are using metabolomic,CRISPR and proteomic approaches to study key metabolic pathways that support hepatitis B virus (HBV) replication, and how viral-induced metabolic reprogramming contributes to oncogenesis. We aim to explore novel diagnosis and therapy strategies for virus-related cancers (HBV-related hepatocellular carcinoma). 

    We are also intreasted in the crosstalk between cell metabolism and signaling pathways, as well as identification of new therapeutic targets for HCC treatment. 

学术兼职：

  中国抗癌协会肿瘤代谢专委会青年委员；

  重庆抗癌协会化疗专业委员会委员；

  Advanced Science、Nat Commun、Clin Transl Med、Genes & Diseases等学术期刊审稿人。

 科研项目：

1. 国家自然科学基金 (面上项目)，糖异生代谢酶PCK1上调组蛋白H3K9me3修饰抑制肝癌的机制研究

2. 国家自然科学基金 (面上项目)，PCK1通过降低O-GlcNAc糖基化修饰抑制肝癌转移的机制研究

3. 国家自然科学基金 (青年基金)，PCK1通过Wnt信号通路抑制肝细胞癌的作用机制研究

4. 国家重点研发计划（子任务），代谢重塑在HBV致病性中的作用机制研究

5. 重庆医科大学 未来医学青年创新团队发展支持计划，“病毒感染与代谢重塑研究团队”

6. 重庆医科大学“新型冠状病毒肺炎”应急专项，SARS-CoV-2假病毒系统的建立及其在抗病毒药物筛选中的应用

7. 重庆市教委科学技术研究计划（青年项目），PCK1下调β-catenin稳定性抑制肝癌EMT的分子机制研究

8. 重庆市教育委员会雏鹰计划研究项目，糖异生关键酶抑制肝癌细胞增殖和迁移能力初探

9. 重庆市自然科学基金（面上项目），PCK1降低Snail1蛋白O-GlcNAc修饰抑制肝癌转移的机制研究 

  论文发表：

1. Zhongqi Feng#, Jiaxin Yin#, Zhirong Zhang#, Zhen Chen, Luyi Huang*, Ni Tang*, Kai Wang*, O-GlcNAcylation of E3 ubiquitin ligase SKP2 promotes hepatocellular carcinoma proliferation. Oncogene, 2024. (IF=8) 

2. Dan Nie#, Xin Tang#, Haijun Deng#, Xiaojun Yang#, Junji Tao, Fengli Xu, Yi Liu, Kang Wu, Kai Wang*, Zhechuan Mei*, Ailong Huang*, Ni Tang*, Metabolic enzyme SLC27A5 regulates PIP4K2A pre-mRNA splicing as a noncanonical mechanism to suppress hepatocellular carcinoma metastasis. Advanced Science, 2024. (IF=15.1)

3. Rui Liu#, Yi Liu#, Wenlu Zhang#, Guiji Zhang#, Zhirong Zhang, Luyi Huang, Ni Tang*, Kai Wang*, PCK1 attenuates tumor stemness via activating the Hippo signaling pathway in hepatocellular carcinoma. Genes & Diseases, 2024. (IF= 6.8) 

4. De-ao Gong#, Peng Zhou#, Wen-yi Chang#, Jia-yao Yang, Yan-lai Zhang, Ai-long Huang, Ni Tang*, Kai Wang*, SPOP promotes CREB5 ubiquitination to inhibit MET signaling in liver cancer. BBA - Molecular Cell Research. 2024. (IF= 5.1) 

5. Peng Zhou#, Wen-yi Chang#, De-ao Gong#, Jie Xia#, Wei Chen, Lu-yi Huang, Rui Liu, Yi Liu, Chang Chen, Kai Wang*, Ni Tang*, Ai-long Huang*, High dietary fructose promotes hepatocellular carcinoma progression by enhancing O-GlcNAcylation via microbiota-derived acetate.Cell Metabolism, 2023. (*Co-corresponding author, IF=29) 

6. Dongmei Gou#, Rui Liu#, Xiaoqun Shan#, Haijun Deng#, Chang Chen#, Jin Xiang, Yi Liu, Qingzhu Gao, Zhi Li, Ailong Huang*, Kai Wang*, Ni Tang*, Gluconeogenic enzyme PCK1 supports S-adenosylmethionine biosynthesis and promotes H3K9me3 modification to suppress hepatocellular carcinoma progression. Journal of Clinical Investigation, 2023. (*Co-corresponding author, IF=19.4) 

7. Qian Ye#, Yi Liu#, Guiji Zhang#, Haijun Deng#, Xiaojun Wang#, Lin Tuo#, Chang Chen, Xuanming Pan, Kang Wu, Jiangao Fan, Qin Pan, Kai Wang*, Ailong Huang*, Ni Tang*, Deficiency of gluconeogenic enzyme PCK1 promotes metabolic-associated fatty liver disease through PI3K/AKT/PDGF axis activation in male mice. Nature Communications, 2023. (*Co-corresponding author, IF=17.6)

8. Jin Xiang#, Chang Chen#, Rui Liu#, Dongmei Gou#, Lei Chang, Haijun Deng, Qingzhu Gao, Wanjun Zhang, Lin Tuo, Xuanming Pan, Li Liang, Jie Xia, Luyi Huang, Ke Yao, Bohong Wang, Zeping Hu, Ailong Huang*, Kai Wang*, Ni Tang*, Gluconeogenic enzyme PCK1 deficiency promotes CHK2 O-GlcNAcylation and hepatocellular carcinoma growth upon glucose deprivation. Journal of Clinical Investigation, 2021. (*Co-corresponding author, IF=19.4)

9. Yang Yang#, Yu Yan#, Jiaxin Yin#, Ni Tang#, Kai Wang#, Luyi Huang, Jie Hu, Zhongqi Feng, Qingzhu Gao, Ailong Huang*, O-GlcNAcylation of YTHDF2 promotes HBV-related hepatocellular carcinoma progression in an N6-methyladenosine-dependent manner. Signal Transduction and Targeted Therapy, 2023.  (#Co-first author, IF=38.1)

10. Rui Liu#, Dongmei Gou#, Jin Xiang#, Xuanming Pan, Qingzhu Gao, Peng Zhou, Yi Liu, Jie Hu, Kai Wang*, Ni Tang*, O-GlcNAc modified-TIP60/KAT5 is required for PCK1 deficiency-induced HCC metastasis. Oncogene, 2021. (*Co-corresponding author, IF=8.8) 

11. Binli Mao#, Vu Thuy Khanh Le-Trilling#, Kai Wang#, Denise Mennerich, Jie Hu, Zhenyu Zhao, Jiaxin Zheng, Yingying Deng, Benjamin Katschinski, Shilei Xu, Guiji Zhang, Xuefei Cai, Yuan Hu, Jianwei Wang, Mengji Lu, Ailong Huang*, Ni Tang*, Mirko Trilling*, Yong Lin*，Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. Emerging Microbes & Infections, 2022. (Co-first author, IF=19.5)

12. Pai Peng#, Hai-jun Deng#, Jie Hu#, Xiao-yu Wei, Jian-jiang Xue, Ting-ting Li, Liang Fang, Bei-zhong Liu, Ai-shun Jin, Feng-li Xu, Kang Wu, Quan-xin Long, Juan Chen, Kai Wang*, Ni Tang*, Ai-long Huang*, Humoral responses in naive or SARS-CoV-2 experienced individuals vaccinated with an inactivated vaccine. Cell Discovery, 2021. (*Co-corresponding author, IF= 38.0)

13. Yi Liu#, Haijun Deng#, Li Liang, Guiji Zhang, Jie Xia, Keyue Ding, Ni Tang*, Kai Wang*, Depletion of VPS35 attenuates metastasis of hepatocellular carcinoma by restraining the Wnt/PCP signaling pathway. Genes & Diseases, 2021. (*Co-corresponding author，IF=7.2)

14. Chang-Long He#, Lu-Yi Huang#, Kai Wang#, Chen-Jian Gu, Jie Hu, Gui-Ji Zhang, Wei Xu, You-Hua Xie*, Ni Tang*, Ai-Long Huang*, Identification of bis-benzylisoquinoline alkaloids as SARS-CoV-2 entry inhibitors from a library of natural products. Signal Transduction and Targeted Therapy, 2021. (#Co-first author, IF=38.1)

15. Pai Peng#, Jie Hu#, Hai-jun Deng, Bei-zhong Liu, Liang Fang, Kai Wang*, Ni Tang*, Ai-long Huang*, Changes of humoral immunity response in SARS-CoV-2 convalescent patients over 8 months. Cellular & Molecular Immunology, 2021. (*Co-corresponding author, IF=22.0)

16. Jie Hu#, Qingzhu Gao#, Changlong He, Ailong Huang, Ni Tang*, Kai Wang*, Development of cell-based pseudovirus entry assay to identify potential viral entry inhibitors and neutralizing antibodies against SARS-CoV-2. Genes & Diseases, 2020. (*Corresponding author，IF=7.1)

17. Qingzhu Gao#, Guiji Zhang#, Yaqiu Zheng#, Yi Yang#, Chang Chen, Jie Xia, Li Liang, Chong Lei, Yuan Hu, Xue-Fei Cai, Wenlu Zhang, Hua Tang, Yaxi Chen, Ailong Huang*, Kai Wang*, Ni Tang*, SLC27A5 deficiency activates NRF2/TXNRD1 pathway by increased lipid peroxidation in HCC. Cell Death & Differentiation, 2020.  (*Co-corresponding author, IF=15.8) 

18. Fan Yang#, Jingjing Li#, Haijun Deng#, Yihao Wang, Chong Lei, Qiujie Wang, Jin Xiang, Li Liang, Jie Xia, Xuanming Pan, Xiaosong Li, Quanxin Long, Lei Chang, Ping Xu, Ailong Huang*, Kai Wang*, Ni Tang*, GSTZ1-1 Deficiency Activates NRF2/IGF1R Axis in HCC via Accumulation of Oncometabolite Succinylacetone. EMBO Journal, 2019. (*Co-corresponding author, IF=11.5)  

19. Jin Xiang#, Yuhong Zhang#, Lin Tuo, Rui Liu, Dongmei Gou, Li Liang, Chang Chen, Jie Xia, Ni Tang, Kai Wang*, Transcriptomic changes associated with PCK1 overexpression in hepatocellular carcinoma cells detected by RNA-Seq. Genes & Diseases, 2020. (Corresponding author，IF=7.1)

20. Jingjing Li#, Qiujie Wang#, Yi Yang, Chong Lei, Fan Yang, Li Liang, Chang Chen, Jie Xia, Kai Wang*, Ni Tang*, GSTZ1 deficiency promotes hepatocellular carcinoma proliferation via activation of the KEAP1/NRF2 pathway. Journal of Experimental & Clinical Cancer Research, 2019. (*Co-corresponding author, IF=11.1)

21. Xuemei Chen#, Yuan Hu#, Wenlu Zhang, Ke Chen, Jie Hu, Xiaosong Li, Li Liang, Xuefei Cai, Jieli Hu, Kai Wang*, Ailong Huang*, Ni Tang*, Cisplatin induces autophagy to enhance hepatitis B virus replication via activation of ROS/JNK and inhibition of the Akt/mTOR pathway. Free Radical Biology and Medicine, 2019. (*Co-corresponding author, IF=7.376)

22. Lin Tuo#, Jin Xiang#, Xuanming Pan#, Jieli Hu, Hua Tang, Li Liang, Jie Xia, Yuan Hu, Wenlu Zhang, Ailong Huang*, Kai Wang*, Ni Tang*, PCK1 negatively regulates cell cycle progression and hepatoma cell proliferation via the AMPK/p27Kip1 axis. Journal of Experimental & Clinical Cancer Research, 2019.(*Co-corresponding author, IF=11.161)  

23. Kai Wang#, Quan-Xin Long#, Hai-Jun Deng#, Jie Hu#, Qing-Zhu Gao, Gui-Ji Zhang, Chang-long He, Lu-Yi Huang, Jie-li Hu, Juan Chen*, Ni Tang*, Ai-Long Huang*, Longitudinal Dynamics of the Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. Clinical Infectious Diseases, 2021. (First author, IF=20.9)

24. Kai Wang#, Wei Lv#, Jianfei Chen#, Shiqi Xie, Hongyan Shi, Haojen Hsu, Wenjing Yu, Ke Xu, Chao Bian, Wolfgang B Fischer, Wolfgang Schwarz, Li Feng*, Bing Sun*, PEDV ORF3 encodes an ion channel protein and regulates virus production. FEBS Letters, 2012.  (First author)

25. Kai Wang#, Shiqi Xie, Bing Sun*. Viral proteins function as ion channels. BBA-Biomembranes, 2011.  (First author)

26. Shiqi Xie#, Kai Wang#, Wenjing Yu, Wei Lv, Ke Xu, Jianwei Wang, Bin Ye, Wolfgang Schwarz, Qi Jin*, Bing Sun*, DIDS blocks a chloride-dependent current that is mediated by the 2B protein of enterovirus 71, Cell Research, 2011. (#Co-first author)

27. Ronghua Zhang#, Kai Wang#, Wei Lv#, Wenjing Yu, Shiqi Xie, Ke Xu, Wolfgang Schwarz, Sidong Xiong*, Bing Sun*, The ORF4a protein of human coronavirus 229E functions as a viroporin that regulates viral production. Biochimica et BBA-Biomembranes, 2014. (#Co-first author)

28. Qingzhu Gao#, Kai Wang#, Ke Chen, Li Liang, Yaqiu Zheng, Yunzhi Zhang, Jin Xiang, Ni Tang *, HBx protein-mediated ATOH1 downregulation suppresses ARID2 expression and promotes hepatocellular carcinoma. Cancer Science, 2017. (#Co-first author)

29. 向进，庹琳，高庆祝，杨翼，梁利，夏杰，唐霓，汪凯*. PCK1影响肝癌细胞迁移能力的研究. 重庆医科大学学报, 2018.

30. 潘璇明，张桂冀，陈雪梅，梁利，唐霓，汪凯*. 果糖-1，6-二磷酸酶1抑制肝癌细胞株HepG2的自噬及增殖. 中华肝脏病杂志, 2019.

31. 龚德敖，唐霓，汪凯*. 斑点型锌指结构蛋白在肿瘤中的作用. 生命的化学，2022.

32. 杨佳瑶，唐霓，汪凯*.己糖胺生物合成途径代谢酶与OGT介导的O-GlcNAc修饰在肿瘤中的研究进展.重庆医科大学学报,2023.